Transaction · 0001193125-26-421529

Buell Jennifer

Buell Jennifer, CEO, reported an open-market or private sale at MiNK Therapeutics, Inc. involving 6938.000000 shares for an estimated $73265.28. Reported holdings after the transaction were 74195.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SCEO
INKTMiNK Therapeutics, Inc.
Trade date
Oct 12, 2026
Filing date
Oct 14, 2026
View on SEC Insider profile
Estimated value-$73.2kShares × reported price
Shares traded6.93k$10.56 per share
Holdings after74.1kDirect
% of reported position traded8.55%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 81,133 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

INKT price since this filing

Daily closing prices, with the filing date and available return windows
INKT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -5.7%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-421529
Common Stock
Transaction date
Oct 12, 2026
Filed Oct 14, 2026, 06:36 PM · 2d delay
Shares
6,938 sh
$10.56 per share
Estimated value
-$73.2k
Computed from shares × price
Holdings after
74,195 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score

+10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").

  2. F2

    Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.

  3. F3

    Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder o…

  4. F4

    On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fift…

Original filing · 0001193125-26-421529
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

INKT